Yael Webb
特許弁護士
Dr. Yael Webb, Ph.D., J.D. is an external professional resource providing subject matter consultant services to Leason Ellis relating to her chemistry and biotech expertise. Dr. Yael Webb is a registered patent attorney focusing on a broad range of chemical, pharmaceutical and biological disciplines. With a strong scientific background in organic and medicinal chemistry, she has over 20 years of experience in patent prosecution and patent portfolio management. Her practice includes preparation and prosecution of patent applications worldwide, validity, patentability and freedom-to-operate analyses, and strategic planning of intellectual property portfolios. In addition to practicing before the United States Patent and Trademark Office, Dr. Webb is a registered Israeli Patent Attorney.
Dr. Webb brings over a decade of drug development expertise in the biotech industry. She has a deep understanding of the entire lifecycle of drug development and assists clients in realizing and protecting innovations from initial discovery and testing through all stages of drug development. Previously, Dr. Webb was at ATON Pharma Inc., where she was part of the team that led to the discovery and development of the histone deacetylase (HDAC) inhibitor SAHA (Vorinostat), now marketed for the treatment of cutaneous T-cell lymphoma.
Dr. Webb received her B.Sc. in chemistry from the Hebrew University in Jerusalem, her Ph.D. in chemistry from Columbia University, and her J.D. from Fordham University School of Law. She conducted her postdoctoral training at Memorial Sloan Kettering Cancer Center. She is the recipient of many honors and awards, including the J. William Fulbright Scholar Award, the Pegram Award for Meritorious Achievement in Chemical Research from Columbia University, and the Accounts of Chemical Research Graduate Award from Columbia University.
Dr. Webb received her B.Sc. in chemistry from the Hebrew University in Jerusalem, her Ph.D. in chemistry from Columbia University, and her J.D. from Fordham University School of Law. She conducted her postdoctoral training at Memorial Sloan Kettering Cancer Center. She is the recipient of many honors and awards, including the J. William Fulbright Scholar Award, the Pegram Award for Meritorious Achievement in Chemical Research from Columbia University, and the Accounts of Chemical Research Graduate Award from Columbia University.
- Fordham University School of Law, J.D., Magna Cum Laude, Order of the Coif, 2021
- Columbia University Ph.D., Chemistry
- Hebrew University, B.Sc., with Honors, Chemistry
- New York
- Registered Patent Attorney: U.S. Patent & Trademark Office
- Israeli Patent Attorney
- ARMGO Pharma, Inc., 2006-2020; Chief Operating Officer, General Counsel 2022- present
- Wilson Sonsini Goodrich & Rosati, Patent Agent/ Associate Patent Attorney, 2020- 2022
- Winston & Strawn LLP, Patent Agent, 2004- 2006
- Aton Pharma, Inc., Associate Director, IP, 2002- 2004
- Eitan, Pearl, Latzer, Cohen- Zedek, Israeli Patent Attorney, 1999- 2002
- Memorial Sloan Kettering Cancer Center, Postdoctoral Fellow, 1997- 1999
- Pegram Award for Meritorious Achievement in Chemical Research, 1997
- Malcolm Miller Distinguished Teaching Award, Columbia University, 1994
- Accounts of Chemical Research Graduate Award, 1993
- William Fulbright Scholar Award, 1992
- Hebrew
- “Safety, pharmacokinetics, and preliminary efficacy of Rycal S 48168 (ARM210) for RYR1-related myopathies: a phase one, open-label dose-escalation trial,” World Muscle Society, 2021
- “Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase,” Clin. Cancer Res., 2001
- “Inhibition of Protein Palmitoylation, raft localization and T cell signaling by 2-bromopalmitate and polyunsaturated fatty acids,” J. Biol. Chem, 2000
- “Photoaffinity Labeling and Mass Spectrometry Identify Ribosomal Protein S3 as Potential Target for Hybrid Polar Cytodifferentiation Agents,” J. Biol Chem, 1999
- ” A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases,” Proc. Natl. Acad. Sci. U.S.A., 1998
- “Second generation hybrid polar compounds are potent inducers of transformed cell differentiation,” Proc. Natl. Acad. Sci. U.S.A., 1996
- “Further studies on the buffer catalyzed cleavage and isomerization of uridyl uridine. Medium and ionic strength effects on catalysis by morpholine, imidazole and acetate buffers help clarify the mechanism involved and their relationship to the mechanism used by the enzyme Ribonuclease and by a ribonuclease mimic,” J. Am. Chem. Soc., 1996